Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
per week
for 24 weeks
// //

Field Trip Health Ltd TSX: FTRP-T

Today's Change
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 6.37
Day High 6.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Field Trip Health Ltd is engaged in the development and delivery of psychedelic therapies. Its operating segments include Clinical Operations, Research, and Corporate. With its Field Trip Discovery, the company's research division, leading the development of the next generation of psychedelic molecules and researching plant-based psychedelics and its Field Trip Health division building centers for psychedelic therapies. Its geographical segments are Canada, United States, and Jamaica.


Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

Field Trip Health Ltd. To Present At The KCSA Psychedelics Virtual Investor Conference On October 13th
- PR Newswire - PRF - Tue Oct 12, 6:30AM CDT
PR Newswire - PRF - CMTX
Tue Oct 12, 6:30AM CDT
/PRNewswire/ -- Field Trip Health Ltd.(TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced that Joseph del Moral, Co-Founder & CEO of Field Trip, will present at the KCSA Psychedelics Investor Conference to be held at  on at .
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
- PR Newswire - PRF - Mon Oct 11, 7:45AM CDT
PR Newswire - PRF - CMTX
Mon Oct 11, 7:45AM CDT
PALM BEACH,  Fla., /PRNewswire/ -- There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, pharmaceutical companies are investing a huge amount of money for novel drug R&D and launches for psychiatric and neurological disorders. The development and discovery of new mental disorders drugs have gained valuable impetus in recent years. Drug makers are moving from conventional drug formulations to the discovery of innovative and improved medications to treat a variety of mental disorders within the mental disorder care industries. A from Grand View Research said that the global central nervous system therapeutic market size, which was valued at 116.2 billion in 2020, is expected to reach by 2028. It added that high unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system therapeutics over the forecast period.  The report continued saying: "The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. … for the development of drug candidates applicable across a wide range of neurological diseases.  Active Biotechs in the markets today include:  . (NASDAQ: KTTA), (NASDAQ: CMPS), (NASDAQ: FTRP) (TSX: FTRP), (NYSE: CYBN), (NASDAQ: ATAI).
Psychedelics Called the 'Next Frontier' for Investors, Also Offer Promising Treatments
- PR Newswire - PRF - Wed Sep 29, 7:31AM CDT
PR Newswire - PRF - CMTX
Wed Sep 29, 7:31AM CDT
/PRNewswire/ -- The fact that psychedelics is a nascent industry doesn't seem to be discouraging savvy investors exploring the opportunities. A recent that "despite being an industry in its early stages, the potential for psychedelic health care is growing, with the market projected to reach by 2027... Smart capital is moving in to take advantage of the opportunity to invest in the next frontier." The multibillion-dollar potential combined with solid promise in psychedelic drug treatments, particularly in the hard-to-treat mental health sector, such as depression, addiction, post-traumatic stress disorder and anxiety, bodes well for pioneering psychedelic companies, including psychedelics; others venturing forward in the space include NASDAQ: SEEL), (TSX: FTRP) (OTCQX: FTRPF), (TSX.V: DMT) and (OTC: MYCOF).
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.16 +31.20% increase
on 09/21/21
Period Open:5.76
Price movement based on the high, low and last over the given period.
7.00 -3.29% decrease
on 10/14/21
+1.01 (+17.53%) increase
since 09/15/21
3-Month 5.16 +31.20% increase
on 09/21/21
Period Open:7.31
Price movement based on the high, low and last over the given period.
7.90 -14.30% decrease
on 08/03/21
-0.54 (-7.39%) decrease
since 07/15/21
52-Week 2.31 +193.07% increase
on 10/23/20
Period Open:2.83
Price movement based on the high, low and last over the given period.
9.88 -31.48% decrease
on 02/11/21
+3.94 (+139.22%) increase
since 10/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies